Diagnostic performance of blood NfL for ALS is superior to other biomarkers of axonal degeneration [such as S100B and progranulin (Steinacker et al., 2017b) or neuroinflammation (Brodovitch et al., 2021)]. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.